Stonepine Capital Management
Latest statistics and disclosures from Stonepine Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, VSTM, ADMA, TENX, EOLS, and represent 64.58% of Stonepine Capital Management's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$102M), TENX (+$15M), ADMA (+$10M), TERN (+$5.3M), CAMP (+$5.1M), ESTA, VSTM, EOLS, SLGL, CRIS.
- Started 23 new stock positions in CNTB, MSLE, PHAT, CADL, KLRS, XLO, TERN, ESTA, SLGL, NMRA. XERS, XBI, OKUR, ARDX, UPB, Bioatla, SIBN, POCI, ARVN, IRD, CTMX, OKYO, SABS.
- Reduced shares in these 10 stocks: NKTR, Indivior, EDSA, ELDN, CRSP, SRZN, IKT, RARE, DAWN, SPRB.
- Sold out of its positions in DAWN, ENTA, FENC, GERN, GOSS, Kezar Life Sciences, KPRX, MIST, Semler Scientific, SPRB. TNYA, RARE, Xilio Therapeutics, Indivior, CRSP.
- Stonepine Capital Management was a net buyer of stock by $127M.
- Stonepine Capital Management has $250M in assets under management (AUM), dropping by 82.32%.
- Central Index Key (CIK): 0001440771
Tip: Access up to 7 years of quarterly data
Positions held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stonepine Capital Management
Stonepine Capital Management holds 72 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Series Trust State Street Spd Put Option (XBI) | 40.9 | $102M | NEW | 800k | 127.73 |
|
| Verastem Com New (VSTM) | 7.0 | $18M | +20% | 3.3M | 5.30 |
|
| Adma Biologics (ADMA) | 6.8 | $17M | +155% | 1.9M | 9.01 |
|
| Tenax Therapeutics Com New (TENX) | 6.2 | $16M | +8105% | 975k | 15.99 |
|
| Evolus (EOLS) | 3.6 | $9.0M | +33% | 2.2M | 4.11 |
|
| Camp4 Therapeutics Corp (CAMP) | 2.5 | $6.1M | +507% | 1.4M | 4.41 |
|
| Nektar Therapeutics Com New (NKTR) | 2.4 | $6.1M | -37% | 85k | 71.95 |
|
| Terns Pharmaceuticals Call Option (TERN) | 2.1 | $5.3M | NEW | 100k | 52.72 |
|
| Zevra Therapeutics Com New (ZVRA) | 1.8 | $4.5M | -15% | 480k | 9.32 |
|
| Abeona Therapeutics Com New (ABEO) | 1.5 | $3.8M | -6% | 847k | 4.48 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.4 | $3.6M | 384k | 9.39 |
|
|
| Establishment Labs Holdings Ord Call Option (ESTA) | 1.3 | $3.2M | NEW | 56k | 56.78 |
|
| Kazia Therapeutics Sponsored Ads (KZIA) | 1.0 | $2.6M | -25% | 345k | 7.44 |
|
| An2 Therapeutics (ANTX) | 1.0 | $2.4M | +13% | 714k | 3.42 |
|
| Alexandria Real Estate Equities Call Option (ARE) | 0.9 | $2.3M | 50k | 46.42 |
|
|
| ACADIA Pharmaceuticals Call Option (ACAD) | 0.9 | $2.2M | 100k | 22.26 |
|
|
| Sol-gel Technologies Shs New (SLGL) | 0.9 | $2.2M | NEW | 28k | 79.22 |
|
| Xoma Royalty Corporation Com New (XOMA) | 0.9 | $2.2M | -39% | 70k | 31.37 |
|
| Aytu Biopharma (AYTU) | 0.9 | $2.2M | -2% | 792k | 2.73 |
|
| Curis (CRIS) | 0.8 | $2.0M | +6178% | 3.7M | 0.55 |
|
| Heron Therapeutics (HRTX) | 0.8 | $1.9M | +94% | 2.4M | 0.80 |
|
| Cytomx Therapeutics Call Option (CTMX) | 0.8 | $1.9M | NEW | 400k | 4.70 |
|
| Xeris Pharmaceuticals Call Option (XERS) | 0.7 | $1.9M | NEW | 320k | 5.80 |
|
| Tela Bio (TELA) | 0.6 | $1.6M | +11% | 2.6M | 0.62 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.6 | $1.6M | -59% | 957k | 1.68 |
|
| Crescent Biopharma (CBIO) | 0.6 | $1.6M | -3% | 85k | 18.37 |
|
| Adicet Bio Com New (ACET) | 0.6 | $1.5M | 222k | 6.81 |
|
|
| Si-bone Call Option (SIBN) | 0.6 | $1.5M | NEW | 115k | 12.63 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.6 | $1.4M | -43% | 335k | 4.13 |
|
| Okyo Pharma Shs New (OKYO) | 0.5 | $1.4M | NEW | 850k | 1.61 |
|
| Mannkind Corp Com New Call Option (MNKD) | 0.5 | $1.3M | +497% | 516k | 2.45 |
|
| Neumora Therapeutics Call Option (NMRA) | 0.5 | $1.2M | NEW | 600k | 1.95 |
|
| Pulmonx Corp (LUNG) | 0.4 | $991k | +57% | 768k | 1.29 |
|
| In8bio Com New (INAB) | 0.4 | $982k | +302% | 663k | 1.48 |
|
| Surrozen Com New (SRZN) | 0.4 | $961k | -70% | 33k | 29.13 |
|
| Delcath Sys Com New Call Option (DCTH) | 0.4 | $928k | +267% | 100k | 9.28 |
|
| Ardelyx Call Option (ARDX) | 0.4 | $899k | NEW | 150k | 5.99 |
|
| Pmv Pharmaceuticals (PMVP) | 0.4 | $878k | -38% | 708k | 1.24 |
|
| Bioage Labs (BIOA) | 0.4 | $875k | +11% | 50k | 17.49 |
|
| Connect Biopharma Hldgs SHS (CNTB) | 0.3 | $812k | NEW | 310k | 2.62 |
|
| Radiopharm Theranostics Sponsored Ads (RADX) | 0.3 | $740k | 51M | 0.01 |
|
|
| Maxcyte (MXCT) | 0.3 | $706k | +114% | 1.0M | 0.70 |
|
| Codexis (CDXS) | 0.3 | $681k | +63% | 418k | 1.63 |
|
| Boundless Bio (BOLD) | 0.3 | $658k | -15% | 598k | 1.10 |
|
| Cybin Com New (HELP) | 0.3 | $644k | -60% | 134k | 4.80 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.3 | $630k | -41% | 269k | 2.34 |
|
| Pasithea Therapeutics Corp Com New (KTTA) | 0.2 | $617k | +202% | 831k | 0.74 |
|
| Satellos Bioscience (MSLE) | 0.2 | $563k | NEW | 100k | 5.63 |
|
| Phathom Pharmaceuticals (PHAT) | 0.2 | $556k | NEW | 50k | 11.11 |
|
| Onkure Therapeutics Com Cl A (OKUR) | 0.2 | $549k | NEW | 133k | 4.14 |
|
| Xilio Therapeutics Com New (XLO) | 0.2 | $540k | NEW | 64k | 8.41 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.2 | $528k | -71% | 100k | 5.29 |
|
| Candel Therapeutics (CADL) | 0.2 | $502k | NEW | 103k | 4.90 |
|
| Precision Optics Corp Inc Ma Com New (POCI) | 0.2 | $439k | NEW | 100k | 4.39 |
|
| Quoin Pharmaceuticals Sponsored Ads (QNRX) | 0.1 | $353k | -31% | 54k | 6.60 |
|
| Upstream Bio (UPB) | 0.1 | $315k | NEW | 35k | 9.00 |
|
| Ocuphire Pharma (IRD) | 0.1 | $313k | NEW | 69k | 4.55 |
|
| Arvinas Ord (ARVN) | 0.1 | $292k | NEW | 28k | 10.60 |
|
| Pliant Therapeutics (PLRX) | 0.1 | $283k | -2% | 225k | 1.26 |
|
| Janux Therapeutics (JANX) | 0.1 | $278k | 20k | 13.90 |
|
|
| Omniab (OABI) | 0.1 | $258k | -76% | 164k | 1.57 |
|
| Compugen Ord (CGEN) | 0.1 | $222k | -65% | 104k | 2.13 |
|
| Sab Biotherapeutics Com New (SABS) | 0.1 | $192k | NEW | 50k | 3.83 |
|
| Edesa Biotech Com New (EDSA) | 0.1 | $157k | -95% | 30k | 5.23 |
|
| CNS Pharmaceuticals (CNSP) | 0.1 | $146k | +24% | 61k | 2.39 |
|
| Processa Pharmaceuticals Com Shs (PCSA) | 0.1 | $139k | +346% | 55k | 2.52 |
|
| Cabaletta Bio (CABA) | 0.1 | $135k | -70% | 50k | 2.69 |
|
| Kalaris Therapeutics (KLRS) | 0.0 | $118k | NEW | 20k | 5.77 |
|
| Eledon Pharmaceuticals (ELDN) | 0.0 | $108k | -96% | 35k | 3.08 |
|
| Ovid Therapeutics (OVID) | 0.0 | $89k | -60% | 40k | 2.22 |
|
| Evaxion As Sponsored Ads (EVAX) | 0.0 | $73k | 20k | 3.72 |
|
|
| Bioatla | 0.0 | $11k | NEW | 65k | 0.16 |
|
Past Filings by Stonepine Capital Management
SEC 13F filings are viewable for Stonepine Capital Management going back to 2015
- Stonepine Capital Management 2026 Q1 filed May 14, 2026
- Stonepine Capital Management 2025 Q4 filed Feb. 13, 2026
- Stonepine Capital Management 2025 Q3 filed Nov. 13, 2025
- Stonepine Capital Management 2025 Q2 filed Aug. 13, 2025
- Stonepine Capital Management 2025 Q1 filed May 14, 2025
- Stonepine Capital Management 2024 Q4 filed Feb. 14, 2025
- Stonepine Capital Management 2024 Q3 filed Nov. 13, 2024
- Stonepine Capital Management 2024 Q2 restated filed Aug. 21, 2024
- Stonepine Capital Management 2024 Q2 filed Aug. 13, 2024
- Stonepine Capital Management 2024 Q1 filed May 15, 2024
- Stonepine Capital Management 2023 Q4 filed Feb. 13, 2024
- Stonepine Capital Management 2023 Q3 filed Nov. 13, 2023
- Stonepine Capital Management 2023 Q2 amended filed Aug. 16, 2023
- Stonepine Capital Management 2023 Q2 filed Aug. 11, 2023
- Stonepine Capital Management 2023 Q1 filed May 12, 2023
- Stonepine Capital Management 2022 Q4 filed Feb. 14, 2023